2026

Organisational Resturucture, Executive Appointment and Board Update

Half-Year Ended 31 December 2025 Information/Appendix 4D

Final Director’s Interest Notice

Resignation of Joint Company Secretary

Quarterly Activities/Appendix 4C Cash Flow Report

Canadian patent secured for PromarkerEso diagnostic test for esophageal adenocarcinoma

Appointment of CEO and Managing Director